In non-small cell lung cancer (NSCLC), patients with low or moderate EGFR expression have shown better responses to EGFR inhibitors than those with high EGFR expression, emphasizing the role of EGFR mutation status in predicting drug sensitivity [38,39]. Here, EGFR is linked to non-small cell lung carcinoma.